Endothelin receptor antagonists: novel agents for the treatment of hypertension?

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• ••A landmark manuscript that reported the discovery ofendothelin and many of its biological actions.
   Google Scholar
• XU D, EMOTO N, GIAID A: ECE-1: a membrane-bound metalloprotease that catalyses the proteolytic activa-tion of big endothelin-1. Cell (1994) 78:473–485.
   PubMed Web of Science ®Google Scholar
• SHIMADA K, TAKAHASHI M, TANZAWA K: Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. (1994) 269:18275–18278.
   PubMed Web of Science ®Google Scholar
• WAGNER 0, CHRIST G, WOJTA J et al.: Polar secretion ofendothelin-1 by cultured endothelial cells. J. Biol. Chem. (1992) 267:16066–16068.
   Google Scholar
• WARNER TD, MITCHELL JA, DE NUCCI G, VANE JR:Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J. Cardiovasc. Pharmacol. (1989) 13:S85–S88.
   PubMed Web of Science ®Google Scholar
• SEO B, OEMAR BS, SIEBENMANN R, VON LUDWIG S,LIISCHER TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89:1203–1208.
   PubMed Web of Science ®Google Scholar
• RABELINK TJ, STROES ESG, BANTEN KP, MORRISON P: Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in CV diseases? Cardiovasc. Res. (1998) 39:543–549.
   Google Scholar
• SCHIFFRIN EL, TOUYZ RM: Vascular biology of endothelin. J. Cardiovasc. Pharmacol. (1998) 32:S2–S13.
   PubMed Web of Science ®Google Scholar
• DOHI Y, HAHN AWA, BOULANGER CM, BÜHLER FR, LIISCHER TF: Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension (1992) 19:131–137.
   PubMed Web of Science ®Google Scholar
• GRAINGER DJ, WITCHELL CM, WEISSBERG PL, METCALFEJC: Mitogens for adult rat aortic vascular smooth muscle cells in serum-free primary culture. Cardiovasc. Res. (1994) 28:1238–1242.
   PubMed Web of Science ®Google Scholar
• CHUA BHL, KREBS CJ, CHUA CC, DIGLIO CA: Endothelin stimulates protein systhesis in smooth muscle cells. Am. J. Physiol. (1992) 262:E412–E416.
   PubMed Web of Science ®Google Scholar
• FUJITANI Y, BERTRAND C: ET-1 cooperates with EGF to induce mitogenesis via a PTX-sensitive pathway in airway smooth muscle cells. Am. J. Physic)]. (1997) 272:C1492–C1498.
   Web of Science ®Google Scholar
• SHARIFI AM, SCHIFFRIN EL: Apoptosis in aorta ofdeoxycorticosterone acetate-salt hypertensive rats: effect of endothelin receptor antagonism. J. Hypertens. (1997) 15:1441–1448.
   PubMed Web of Science ®Google Scholar
• SHICHIRI M, KATO H, MARUMO F, HIRATA Y: Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension (1997) 30:1198–1203.
   PubMed Web of Science ®Google Scholar
• THARAUX PL, CHATZIANTONIOU C, CASSELAS D, FOUASSIER L, ARDAILLOU R, DUSSAULE JC: Vascular endothelin-1 gene expression and synthesis and effects on renal Type I collagen synthesis and nephro-angiosclerosis during nitric oxide synthase inhibition in rats. Circulation (1999) 99:2185–2191.
   PubMed Web of Science ®Google Scholar
• HOCHER B, GEORGE I, REBSTOCK J et al.: Endothelin system-dependent cardiac remodeling in renovas-cular hypertension. Hypertension (1999) 33:816–822.
   PubMed Web of Science ®Google Scholar
• GUIDRY C: Extracellular matrix contraction by fibroblasts: peptide promoters and second messen-gers. Cancer Metastasis Rev. (1992) 11:45–54.
   PubMed Web of Science ®Google Scholar
• POTTER GS, JOHNSON RJ, FINK GD: Role of endothelin in hypertension of experimental chronic renal failure. Hypertension (1997) 30:1578–1584.
   PubMed Web of Science ®Google Scholar
• MORTENSEN LH, FINK GD: Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats. Hypertension (1992) 19:676–680.
   PubMed Web of Science ®Google Scholar
• WILKINS FC, ALBEROLA A, MIZELLE HL, OPGENORTH TJ,GRANGER JP: Chronic pathophysiological circulating endothelin levels produce hypertension in conscious dogs. J. Cardiovasc. Pharmacol. (1993) 22 (Suppl. 8):S325–S327.
   Google Scholar
• RABELINK TJ, KAASJAGER KAH, BOER P, STROES EG, BRAAM B, KOOMANS HA: Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. (1994) 46:376–381.
   PubMed Web of Science ®Google Scholar
• YOKOKAWA K, TAHARA H, KOHNO M et al.: Hyperten-sion associated with endothelin-secreting malignant hemangioendothelioma. Ann. Int. Med. (1991) 114:213–215.
   PubMed Web of Science ®Google Scholar
• SAITO Y, NAKAO K, MUKOYAMA M, IMURA H: Increasedplasma endothelin level in patients with essential hypertension [letter]. N Engl. J. Med. (1990) 322:205.
   PubMed Web of Science ®Google Scholar
• ZOCCALI C, LEONARDIS D, PARLONGO S, MALLAMACI F,POSTORINO M: Urinary and plasma endothelin-1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrof Dialysis Transpl. (1995) 10:1320–1323.
   PubMed Web of Science ®Google Scholar
• JANUSZEWICZ A, LAPINSKI M, SYMONIDES B et al.: Elevated endothelin-1 plasma concentration in patients with essential hypertension. J. Cardiovasc. Risk (1998) 1:81–85.
   Google Scholar
• AMOROSO A, COSSU MF, MARIOTTI A et al.: Increasedplasma levels of endothelin in patints with essential arterial hypertension. Riv. Eur. Sci. Med. Farmacol (1996) 18:33–37.
   PubMedGoogle Scholar
• SHICHIRI M, HIRATA Y, ANDO K et al.: Plasmaendothelin levels in hypertension and chronic renal failure. Hypertension (1990) 15:493–496.
   PubMed Web of Science ®Google Scholar
• DAVENPORT AP, ASHBY MJ, EASTON P et al.: A sensitiveradioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin. Sci. (1990) 78:261–264.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI T, YANAGISAWA M, IIDA K et al.: Age- andsex-related variation of plasma endothelin-1 concen-tration in normal and hypertensive subjects. Am. Heart J. (1992) 123:1092–1093.
   PubMed Web of Science ®Google Scholar
• VEGLIO F, BERTELLO P, PINNA G et al.: Plasmaendothelin in essential hypertension and diabetes mellitus. J. Human Hypertens. (1993) 7:321–325.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, THIBAULT G: Plasma endothelin inhuman essential hypertension. Am. J. Hypertens. (1991) 4:303–308.
   PubMed Web of Science ®Google Scholar
• SORENSEN SS, EGEBLAD M, EISKJAER H etal.: Endothelinin renovascular and essential hypertension. Blood Pressure (1994) 3:364–369.
   Google Scholar
• FERNANDEZ-CRUZ A, MARTIN P, FERNANDEZ L et al. Plasma endothelin is increased in young essential hypertensives but not in elderly essential or diabetic hypertensives. J. Hypertens. (1993) 11 (Suppl 5) S146-S147 © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• ERGUL S, PARISH DC, PUETTE D, ERGUL A: Racial differ- ences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension (1996) 28:652–655.
   PubMed Web of Science ®Google Scholar
• ••This manuscript presents an important heterogeneity of ETlevels in hypertensive patients. The results suggest that African Americans may benefit more importantly than Caucasians from ET-receptor antagonists.
   Google Scholar
• WIDIMSKY J, JR., HORKY K, DVORAKOVA J: Plasma endothelin-1,2 levels in mild and severe hypertension. Hypertens. (1991) 9 (suppl.):5194–S195.
   Google Scholar
• LEMNE CE, LUNDEBERG T, THEODORSSON E, DE FAIREU: Increased basal concentrations of plasma endothelin in borderline hypertension. J. Hypertens. (1994) 12:1069–1074.
   PubMed Web of Science ®Google Scholar
• NOLL G, WENZEL RR, SCHNEIDER M et al.: Increasedactivation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 93:866–869.
   PubMed Web of Science ®Google Scholar
• POCH E, JIMENEZ W, FEU F et al.: Increased plasmaendothelin concentration in atherosclerotic renovas-cular hypertension. Nephron (1995) 71:291–296.
   PubMedGoogle Scholar
• BALDYS-WALIGORSKA A, SZYBINSKI Z: Plasma endothelin 1/2 levels in healthy blood donors and in hypertensive patients: clinical application. Endocr. Regul. (1993) 27:83–87.
   PubMedGoogle Scholar
• HAAK T, JUNGMANN E, FELBER A, HILLMANN U, USADELKH: Increased plasma levels of endothelin in diabetic patients with hypertension. Am. J. Hypertens. (1992) 5:161–166.
   PubMed Web of Science ®Google Scholar
• DEMUTH K, BLACHER J, GUERIN AP et al.: Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol. Dialysis Transpl. (1998) 13:375–383.
   PubMed Web of Science ®Google Scholar
• LEBEL M, GROSE JH, KINGMA I, LANGLOIS S: Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythro-poietin replacement therapy. Clin. Exp. Hypertens. (1994) 16:565–575.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, CERNACEK P, COSTELLO KB, ROULEAU JL:Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation (1992) 85:510–517.
   PubMed Web of Science ®Google Scholar
• ARENDT RM, WILBERT-LAMPEN U, HEUCKE L, SCHMOECKEL M, SUHLER K, RICHTER WO: Increased endothelin plasma concentrations in patients with coronary artery disease or hyperlipoproteinemia without coronary events. Res. Exp. Med. (1993) 193:225–230.
   PubMedGoogle Scholar
• LERMAN A, HOLMES DR, JR., BELL MR, GARRATT KN, NISHIMURA RA, BURNETT JC, JR.: Endothelin in coronary endothelial dysfunction and early athero-sclerosis in humans. Circulation (1995) 92:2426–2431.
   Google Scholar
• LERMAN A, EDWARDS BS, HALLETT JW, HEUBLEIN DM,SANDBERG SM, BURNETT JC, JR.: Circulating and tissue endothelin immunoreactivity in advanced atheroscle-rosis. N Eng]. J. Med. (1991) 325:997–1001.
   Google Scholar
• LARIVIERE R, DAY R, SCHIFFRIN EL: Increased expres-sion of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension (1993) 21:916–920.
   PubMed Web of Science ®Google Scholar
• NISHIKIBE M, TSUCHIDA S, OKADA M et al.: Antihyper-tensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertension model. Life Sci. (1993) 52:717–724.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V, BURRI K et al.: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (1993) 365:759–761.
   PubMed Web of Science ®Google Scholar
• MOREAU P, D'USCIO LV, TAKASE H, SHAW S, BARTON M,LOSCHER TF: Angiotensin II increases tissue endothelin and induced vascular hypertrophy in vivo: reversal by ETA-receptor antagonist. Circulation (1997) 96:1593–1597.
   PubMed Web of Science ®Google Scholar
• •First direct demonstration of the in vivo involvement of ET mediating some of the responses attributed to angiotensin
   Google Scholar
• HERIZI A, JOVER B, BOURIQUET N, MIMRAN A: Preven- tion of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension (1998) 31:10–14.
   PubMed Web of Science ®Google Scholar
• LI JS, KNAFO L, TURGEON A, GARCIA R, SCHIFFRIN EL: Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am. J. Physic)]. (1996) 40:H88–H93.
   Google Scholar
• EHMKE H, FAULHAER J, MUNTER K, KIRCHENGAST M, WIESNER RJ: Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension (1999) 33:954–960.
   PubMed Web of Science ®Google Scholar
• D'USCIO L, BARTON M, SHAW S, MOREAU P, LOSCHER TF: Structure and function of small arteries in salt-induced hypertension: Effects of chronic ETA-receptor blockade. Hypertension (1997) 30:905–911.
   PubMed Web of Science ®Google Scholar
• KASSAB S, MILLER MT, NOVAK J, RECKELHOFF J, CLOWER B, GRANGER JP: Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension (1998) 31:397–402.
   PubMed Web of Science ®Google Scholar
• BARTON M, D'USCIO LV, SHAW S, MEYER P, MOREAU P, LOSCHER TF: ETA-receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension (1998) 31:499–504.
   PubMed Web of Science ®Google Scholar
• LI JS, LARIVIERE R, SCHIFFRIN EL: Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy. Hypertension (1994) 24:183–188.
   PubMed Web of Science ®Google Scholar
• ••First report showing an impressive effect of ET-receptorantagonists on small artery hypertrophy, despite modest antihypertensive efficacy.
   Google Scholar
• KARAM H, HEUDES D, HESS P et al.: Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc. Res. (1996) 31:287-295. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• MATSUMURA Y, HASHIMOTO N, TAIRA S et al.: Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension (1999) 33:759–765.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, TURGEON A, DENG LY: Effects of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hyperten-sion in rats. Br. J. Pharmacol. (1997) 121:935–40.
   PubMed Web of Science ®Google Scholar
• LI J-S, SCHIFFRIN EL: Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension (1995) 25:495–500.
   PubMed Web of Science ®Google Scholar
• KARAM H, HEUDES D, BRUVENAL P et al: Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antago-nism. Hypertension (1996) 28:379–385.
   Google Scholar
• BLEZER ELA, NICOLAY K, GOLDSCHMEDING R et al.: Early, but not late-onset, endothelin A receptor blockade can modulate hypertension, cerebral edema and proteinuria in stroke-prone hypertensive rats. Hypertension (1999) 33:137–144.
   PubMed Web of Science ®Google Scholar
• •One of few reports that studied prevention and regression of cardiovascular alterations with an ET-receptor antagonist. In addition, the effect of the drug on mortality was also assessed in a model of hypertension-induced stroke (SHR-SP).
   Google Scholar
• STASCH J-P, HIRTH-DIETRICH C, FROBEL K, WEGNER M: Prolonged endothelin blockade prevents hyperten-sion and cadiac hypertrophy in stroke-prone sponta-neously hypertensive rats. Am. J. Hypertens. (1995) 8:1128–1134.
   PubMed Web of Science ®Google Scholar
• CHILLON J-M, HEISTAD DD, BAUMBACH GL: Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension (1996) 27:794–798.
   PubMed Web of Science ®Google Scholar
• RICHARD V, HOGIE M, CLOZEL M, LOFFLER B-M, THUILLEZ C: In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation (1995) 91:771–775.
   PubMed Web of Science ®Google Scholar
• THOMPSON A, VALERI CR, LIEBERTHAL W: Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in the rat. Am. J. Physic)]. (1995) 269:H743–H748.
   Web of Science ®Google Scholar
• MOREAU P, TAKASE H, KONG CF, SHAW S, LOSCHER TF: Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hyperten-sion. Hypertension (1997) 29:763–769.
   PubMed Web of Science ®Google Scholar
• SVENTEK P, TURGEON A, SCHIFFRIN EL: Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antago-nism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation (1997) 95:240–244.
   PubMed Web of Science ®Google Scholar
• FORTEPIANI LA, JANVIER JJ, ORTIZ MC, ATUCHA NM, GARCIA-ESTAN J: Effect of endothelin blockade on pressure natriuresis in nitric oxide-deficient hypertensive rats. J. Hypertens. (1999) 17:287–291.
   PubMed Web of Science ®Google Scholar
• POLLOCK DM Chronic studies on the interaction between nitric oxide and endothelin in cardiovascular and renal function. Clin. Exp. Pharmacol. Physiol (1999) 26:258–261.
   PubMed Web of Science ®Google Scholar
• MOREAU P: Endothelin in hypertension: a role for receptor antagonists? Cardiovasc. Res. (1998) 39:534–542.
   Google Scholar
• RIZZONI D, PORTERI E, CASTELLANO M et al.: Vascular hypertrophy amd remodeling in secondary hyperten-sion. Hypertension (1996) 28:785–790.
   PubMed Web of Science ®Google Scholar
• •The only report available documenting the type of remodel-ling occurring in several forms of human hypertension.
   Google Scholar
• HEAGERTY AM, AALKJAER C, BUND SJ, KORSGAARD N, MULVANY MJ: Small artery structure in hypertension: Dual process of remodelling and growth. Hypertension (1993) 21:391–397.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY, SVENTEK P, Day R: Enhanced expression of endothelin-1 gene in resitance arteries in severe human essential hypertension. J. Hypertens. (1997) 15:57–63.
   PubMed Web of Science ®Google Scholar
• RABELINK TJ, KAASJAGER KAH, STROES ESG: Endothelin in renal pathophysiology: From experimental to therapeutic application. Kidney Int. (1996) 50:1827–1833.
   PubMed Web of Science ®Google Scholar
• •Excellent recent review on the role of ET on the renal function in hypertension and renal failure models.
   Google Scholar
• TAKAYANAGI R, HASHIGUCHI T, OHASHI M, NAWATA H: Regional distribution of endothelin receptor in porcine cardiovascular tissues. Regul. PepL (1990) 27:247–255.
   PubMed Web of Science ®Google Scholar
• TOBIAN L, JOHNSON MA, HANLON S, BARTEMES K: A glomerular defect in prehypertensive Dahl S rats, which limits their capacity to increase GFR. Am. J. Hypertens. (1989) 2:557–559.
   PubMed Web of Science ®Google Scholar
• BARTON M, D'USCIO LV, SHAW S, MOREAU P, LOSCHER TF: Selective endothelial dysfunction in the renal artery in Dahl hypertension: Role of NO, endothelin and endothelium-derived contracting factor [abstract]. Hypertension (1997) 30:508.
   Google Scholar
• KASSAB S, NOVAK J, MILLER T, KIRCHER K, GRANGER J: Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension (1997) 30:682–686.
   PubMed Web of Science ®Google Scholar
• •Elegant study demonstrating a direct beneficial effect of ET-receptor antagonists on the renal function of Dahl-salt sensitive rats.
   Google Scholar
• OHUCHI T, KUWAKI T, LING GY et al: Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am. J. Physiol (1999) 276:R1071–R1077.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V: The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist Ro 46-8443. EEGS Lett. (1996) 383:42–45.
   Google Scholar
• KRUM H, VISKOPER RV, LACOURCIERE Y, BUDDE M, CHARLON V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl. J. Med. (1998) 338:784–790.
   PubMed Web of Science ®Google Scholar
• ••First account of the potential effectiveness of ET-receptorantagonists to treat essential hypertension (proof of concept study).C
   Google Scholar
• HAYNES WG, FERRO CJ, WEBB DJ: Bosentan in essential hypertension [letter; comment]. N Engl. J. Med. (1998) 339:346–347.
   PubMedGoogle Scholar
• WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacoki-netics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol Ther. (1996) 60:124–137.
   PubMed Web of Science ®Google Scholar
• HAYNES WG, FERRO CJ, O'KANE KP, SOMMERVILLE D, LOMAX CC, WEBB DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 93:1860–1870.
   PubMed Web of Science ®Google Scholar
• PLUMPTON C, FERRO CJ, HAYNES WG, WEBB DJ, DAVENPORT AP: The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br. J. Pharmacol (1996) 119:311–314.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist-mediated vasodila-tation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• •In vivo demonstration in humans of the potential haemody-namic advantage of blocking only ETA-receptors rather than both ETA- and ETB-receptors.
   Google Scholar
• STRACHAN FE, SPRATT JC, WILKINSON IB, JOHNSTON NR, GRAY GA, WEBB DJ: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 33:581–585.
   PubMed Web of Science ®Google Scholar
• CARDILLO C, KILCOYNE CM, WACLAWIW M, CANNON RO, 3RD, PANZA JA: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (1999) 33:753–758.
   PubMed Web of Science ®Google Scholar
• •Forearm blood flow experiments suggesting an enhanced contribution of ETB-receptors to vasoconstriction in hypertensive patients.
   Google Scholar
• CLOZEL M, RAMUZ H, CLOZEL J-P et al.: Preclinical and clinical pharmacology of tezosentan, a new endothelin receptor antagonsit designed for parental use. Proceedings of the 6th International Conference on Endothelin. Montreal, Canada (1999):Abstract 49.
   Google Scholar
• SPEIKER LE, NOLL G, MITROVIC M et al. Acute hemody-namic and biochemical effects of selective ETA receptor blockade in patients with congestive heart failure. Proceedings of the 6th International Conference on Endothelin. Montreal, Canada (1999):Abstract 52.
   Google Scholar
• Proceeding of the American Society of Nephrology. J. Am. Soc. Nephrol. (1998):Abstracts.
   Google Scholar
• HONING MLH, YANG F, PADLEY R, MORRISON PJ, RABELINK TJ: ABT-627, a selective ETA-receptor antago-nist, reduces albuminuria in patients with diabetes mellitus. Proceeding from the 6th International Conference on Endothelin. Montreal, Canada (1999):Abstract 46.
   Google Scholar
• WEIR MR: Salt intake and hypertensive renal injuy in African Americans. Am. J. Hypertens. (1995) 8:635–644.
   PubMed Web of Science ®Google Scholar
• SEVER P: The heterogeneity of hypertension: whydoesn't every patient respond to every antihyperten-sive drug? J. Cardiovasc. Pharmacol. (1998) 31 (Suppl. 2):S1–54.
   Google Scholar
• BOURIQUET N, DUPONT M, HERIZI A, MIMRAN A, CASSELAS D: Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin. Hypertension (1996) 27:382–391.
   PubMed Web of Science ®Google Scholar
• KADDOURA S, FIRTH JD, BOHELER KR, SUGDEN PH, POOLE-WILSON PA: Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: acute effects of bosentan, an orally active, mixed endothelin ETA and El'a receptor antagonist. Circula-tion (1996) 93:2068–2079.
   PubMed Web of Science ®Google Scholar
• FRACCAROLLO D, HU K, GALUPPO P, GAUDRON P, ERTLG: Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: Possible involvement of myocardial endothelin system in ventricular remodeling. Circulation (1 9 9 7) 96:3963-3973.
   Google Scholar
• •Study comparing short and long-term administration of an ET-receptor antagonist after MI. The results demonstrate a beneficial role of ET-receptor blockade during prolonged therapy on heart remodelling and haemodynamic parameters.
   Google Scholar
• ROCKEY DC, CHUNG JJ: Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J. Clin. Invest. (1996) 98:1381–1388.
   PubMedGoogle Scholar
• STEWART DJ, KUBAC G, COSTELLO KB, CERNACEK P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol. (1991) 18:38–43.
   PubMed Web of Science ®Google Scholar
• RAVENSBERGEN J, RAVENSBERGEN JW, KRUGER JBK, HILLEN B, HOOGSTRATEN HW: Localizing role of hemodynamics in atherosclerosis in several human vertebrobasilar junction geometries. Arterioscler. Thromb. Vasc. Biol. (1998) 18:708–716.
   PubMed Web of Science ®Google Scholar
• TRAUB 0, BERK BC: Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotec-tive force. Arterioscler. Thromb. Vasc. Biol. (1998) 18:677–685.
   PubMed Web of Science ®Google Scholar
• •Well written and well illustrated review article on the signal transduction of a mechanical force (shear stress) to produce an endothelial response, and its relevance to atherosclerosis.
   Google Scholar
• ZIEGLER T, BOUZOURENE K, HARRISON VJ, BRUNNER HR, HAYOZ D: Influence of oscillatory and unidirec-tional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. (1998) 18:686–692.
   PubMed Web of Science ®Google Scholar
• ••Excellent study using a sophisticated system to try to isolatemechanical components of the normal circulation and measure their individual and combined impact on the endothelial production of nitric oxide and ET.
   Google Scholar
• BOULANGER CM, TANNER FC, BEA ML, HAHN AWA, WERNER A, LeSCHER TF: Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. (1992) 70:1191–1197.
   PubMed Web of Science ®Google Scholar
• KOWALA MC, ROSE PM, STEIN PD et al.: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am. J. Pathol (1995) 146:819–826.
   PubMed Web of Science ®Google Scholar
• BARTON M, HAUDENSCHILD CC, D'USCIO LV, SHAW S, MUNTER K, LUSCHER TF: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95:14367–14372.
   PubMed Web of Science ®Google Scholar
• ••Convincing demonstration that ET-receptor antagonism canprevent atherosclerosis in a very severe animal model.
   Google Scholar
• ZEIHER AM, IHLING C, PISTORIUS K, SCHACHINGER V, SCHAEFER HE: Increased tissue endothelin immunore-activity in atherosclerotic lesions associated with acute coronary syndromes. Lancet (1 9 9 4) 344:1405-1406.
   Google Scholar
• OKADA M, KOBAYASHI M, MARUYAMA H et al.: Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hyperten-sive rats. Clin. Exp. Pharmacol Physiol (1995) 22:763–768.
   PubMed Web of Science ®Google Scholar
• •Elegant demonstration of the pressure-independent protec-tion of cerebrovascular lesions by an ET-receptor antagonist in SHR-SP.
   Google Scholar
• MOREAU P, NAVA E, TAKASE H, LUSCHER TF: Local regulation of vascular function: focus on endothelium-dependent mechanisms in normoten-sion, hypertension and atherosclerosis. In: Pathophysi-ology of Hypertension. Zanchetti A, Mancia G (Eds.) Elsevier, Amsterdam (1997) :975–1006.
   Google Scholar
• ROSENDORFF C: Endothelin, vascular hypertrophy, and hypertension. Cardiovasc. Drugs Ther. (1997) 10:795–802.
   PubMed Web of Science ®Google Scholar
• •Good recent review on a subject very similar to that presented in this manuscript.
   Google Scholar
• D'USCIO LV, MOREAU P, SHAW S, TAKASE H, BARTON M, LUSCHER TF: Effects of chronic ETA-receptor blockade in angiotensin ffinduced hypertension. Hypertension (1997) 29:435–441.
   PubMed Web of Science ®Google Scholar
• HORKY K, JINDRA A, PELESKA J et al.: Plasma concentra-tions of some cardiovascular humoral factors in essential hypertension and their changes during the treatment with converting enzyme inhibitor lisinopril. Sb. Lek. (1993) 94:155–161.
   PubMedGoogle Scholar
• GALATIUS-JENSEN S, WROBLEWSKI H, EMMELUTH C, BIE P, HAUNSO S, KASTRUP J: Plasma endothelin in conges-tive heart failure: effect of the ACE inhibitor, fosino-pril. Cardiovasc. Res. (1996) 32:1148–1154.
   PubMed Web of Science ®Google Scholar
• DIPASQUALE P, VALDES L, ALBANO V et al: Early captopril treatment reduces plasma endothelin concentrations in the acute and subacute phases of myocardial infarction: a pilot study. J. Cardiovasc. Pharmacol. (1997) 29:202–208.
   PubMed Web of Science ®Google Scholar
• UEMASU J, MUNEMURA C, FUJIHARA M, KAWASAKI H: Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin. Nephrol. (1994) 41:150–152.
   PubMed Web of Science ®Google Scholar
• D'USCIO LV, SHAW S, BARTON M, LUSCHER TF: Losartan but not verapamil inhibits angiotensin II- induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension (1998) 3 1:1305–1310.
   Google Scholar
• LARIVIERE R, LEBEL M, KINGMA I, GROSE JH, BOUCHER D: Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am. J. Hypertens. (1998) 11:989–997.
   PubMed Web of Science ®Google Scholar
• LOVE MP, HAYNES WG, GRAY GA, WEBB DJ, MCMURRAY JJ: Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 94:2131–2137.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, CORNA D, MAFFI R, BENEDETTI G, ZOJA C, REMUZZI G: Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. (1998) 54:353–359.
   PubMed Web of Science ®Google Scholar
• GOTO K, KASUYA Y, MATSUKI N et al.: Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc. Natl. Acad. Sci. USA (1989) 86:3915–3918.
   PubMed Web of Science ®Google Scholar
• KIOWSKI W, LUSCHER TF, UNDER L, BeHLER FR: Endothelin-1-induced vasoconstriction in humans: Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation (1991) 83:469–475.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA T, HAZAMA H, HAMADA E et al.: Endothelin-1 and vasopressin activate Ca(2+)-permeable non-selective cation channels in aortic smooth muscle cells: mechanism of receptor-mediated Ca2+ influx. J. Mol. Cell. Cardiol (1996) 28:707–722.
   PubMed Web of Science ®Google Scholar
• KOMURO T, MIWA S, ZHANG XF et al: Physiological role of Ca2+-permeable nonselective cation channel in endothelin-1-induced contraction of rabbit aorta. J. Cardiovasc. Pharmacol. (1997) 30:504–509.
   PubMed Web of Science ®Google Scholar
• BKAILY G, NAIK R, D'ORLEANS-JUSTE P, WANG S, FONG CN: Endothelin-1 activates the R-type Ca2+ channel in vascular smooth-muscle cells. J. Cardiovasc. Pharmacol (1995) 26 (Suppl. 3):S303–306.
   Google Scholar
• KAASJAGER KAH, VAN RIJN HJ, KOOMANS HA, RABELINK TJ: Interactions of nifedipine with renovascular effects of endothelin in humans. J. Pharmacol. Exp. Ther. (1995) 275:306–311.
   PubMed Web of Science ®Google Scholar
• BARMAN SA, PAULY JR: Mechanism of action of endothelin-1 in the canine pulmonary circulation. J. Appl. Physiol. (1995) 79:2014–2020.
   PubMed Web of Science ®Google Scholar
• KRUM H, GU A, WILSHIRE-CLEMENT M et al: Changes in plasma endothelin-1 levels reflect clinical response to beta- blockade in chronic heart failure. Am. Heart J. (1996) 131:337–341.
   PubMed Web of Science ®Google Scholar
• GARLICHS CD, ZHANG H, MUGGE A, DANIEL WG: Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur. J. Clin. Invest. (1999) 29:12–16.
   PubMed Web of Science ®Google Scholar
• ITO H, HIROE M, HIRATA Y et al.: Endothelin ETA-receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation (1994) 89:2198–2203.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, QIU C, OSTERWALDER R et al.: Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass. J. Cardiovasc. Pharmacol. (1999) 33:611–618.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, REMUZZI G: Endothelin antagonists. Lancet (1999) 353 (9147):133–138.
   PubMed Web of Science ®Google Scholar
• MASUDA Y, SUGO T, KIKUCHI T et al.: Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo ED-alpha-aspartyl- 3 -[(4-phenylpiperazin-1 -y1) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thieny0 glycyl-L-leucyl-D-tryptophylklisodium salt], in human endothelinA and endothelinB receptors. J. Pharmacol. Exp. Ther. (1996) 279:675–685.
   PubMedGoogle Scholar
• NAMBI P, PULLEN M, WU HL et al.: Nonpeptide endothelin receptor antagonists. VII: Binding charac-teristics of [311]SB 209670, a novel nonpeptide antago-nist of endothelin receptors. J. Pharmacol Exp. Ther. (1996) 277:1567–1571.
   Google Scholar
• BIALECKI RA, STINSON-FISHER C, MURDOCH W, BERTELSEN D, DESIATO M, RUMSEY W: A novel orally active endothelin-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat. Chest (1998) 114:91S.
   PubMed Web of Science ®Google Scholar